Silaja Cheruvu, R3.  What’s the BEST way to prevent diabetes in high risk patients?  By doing nothing?  With lifestyle changes?  With medication?

Slides:



Advertisements
Similar presentations
The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
Advertisements

Evidence-Based Medicine Critical Appraisal of Therapy Department of Medicine - Residency Training Program Tuesdays, 9:30 a.m. - 12:00 p.m., UW Health Sciences.
1 Outcome evaluation of health promotion/life style change Wei-Chu Chie.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
The Diabetes Prevention Program 10 Year follow-up Long-term Follow-up to A Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
Clinical trial The Way We Make Progress Against Disease Prof. Ashry Gad Mohamed Prof. of Epidemiology College of Medicine & KKUH.
The Diabetes Prevention Program A U.S. Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.
Obstructive Sleep Apnea
Title slide Include name of program and logo here Reference program as part of the National Diabetes Prevention Program led by CDC.
I CAN Prevent Diabetes! Individuals and Communities Acting Now to Prevent Diabetes Recruitment Discussion 2012.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
Reducing the Risk of Developing Diabetes Chapter 5 Thomas Ransom, Ronald Goldenberg, Amanda Mikalachki, Ally PH Prebtani, Zubin Punthakee Canadian Diabetes.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Absolute, Relative and Attributable Risks. Outcomes or differences that we are interested in:  Differences in means or proportions  Odds ratio (OR)
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
JAMA: Users’ guide to evidence-based medicine
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
Journal Club by Dr Mohammad Al-Busafi R4.  Compare efficacy of  Ibuprofen 10 mg /kg  Paracetamol and codeine ( cocodamol ! ) 1mg/kg (codeine component.
Reducing the Risk of T2DM: What Works?
Critiquing for Evidence-based Practice: Therapy or Prevention M8120 Columbia University Suzanne Bakken, RN, DNSc.
How to Analyze Therapy in the Medical Literature (part 2)
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.
Understanding real research 4. Randomised controlled trials.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH 1436(2014)
Intermountain Diabetes Prevention Program : Stepping Back to Move Forward Elizabeth Joy, MD, MPH Medical Director, Clinical Outcomes Research Family Medicine.
Literature Appraisal Effectiveness of Therapy. Measures of treatment effect Statistical significance Odds ratio Relative risk Absolute risk reduction.
Evidence and Experience Based Medicine Successfully implementing research into your practice.
Methods for Pressure Ulcer Prevention Jeremy Doody Biomedical Engineering /6/15.
Prevention Of Diabetes. Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
Diabetes Prevention Program (DPP)
Risks & Odds Professor Kate O’Donnell. When talking about the chance of something happening, e.g. death, hip fracture, we can talk about: risk and relative.
Compliance Original Study Design Randomised Surgical care Medical care.
Investigation 5-2 Did the prevention strategy work? xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx.
Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.
/ 161 Saudi Diploma in Family Medicine Center of Post Graduate Studies in Family Medicine EBM Therapy Articles Dr. Zekeriya Aktürk
Course: Research in Biomedicine and Health III Seminar 4: Critical assessment of evidence.
بسم الله الرحمن الرحیم.
CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH.
CRITICAL APPARAISAL OF A PAPER ON THERAPY 421 CORSE EVIDENCE BASED MEDICINE (EBM)
Critical appraisals: Treatment. CLINICAL TRIAL = a prospective study comparing the effect and value of intervention(s) against a control in human beings.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH 1436(2015)
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Objectives (Chapter 20) Comparing two proportions  Comparing 2 independent samples  Confidence interval for 2 proportion  Large sample method  Plus.
 Exercise and Vitamin D in Fall Prevention Among Older Women Journal Club, June 2016 Theresa Drallmeier and Tu Dao.
20. Comparing two proportions
EBM R1張舜凱.
HelpDesk Answers Synthesizing the Evidence
CRITICAL APARAISAL OF A PAPER ON THERAPY
FM Journal Club February, 2011.
Diabetes and Obesity Journal Club Carina Signori, D.O., M.P.H.
Copyright © 2011 American Medical Association. All rights reserved.
Neal B, et al. Diabetes Care 2015;38:403–411
Diabetes Journal Club Julie Shah.
Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results
DiRECT (Diabetes Remission Clinical Trial)
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
Noninvasive Positive-Pressure Ventilation In COPD
Reducing the Risk of Developing Diabetes
EBM – therapy Dr. Tina Dewi J , dr., SpOG
Associate Fellow, Centre for Evidence-based Medicine, Oxford
How to assess an abstract
Presentation transcript:

Silaja Cheruvu, R3

 What’s the BEST way to prevent diabetes in high risk patients?  By doing nothing?  With lifestyle changes?  With medication?

 27 centers   3234 participants  “High Risk” ◦ 25 years old ◦ BMI>24 ◦ Elevated fasting glucose, 2 hour GTT

 Placebo arm=Standard lifestyle recommendations  Metformin arm  Troglitazone arm (discontinued early)  Intensive Lifestyle Modification arm ◦ Achieve/maintain a 7% weight loss ◦ 150 minutes/week ◦ 16 week curriculum

 Placebo arm ◦ 77%  Metformin arm ◦ 72%  Intensive Lifestyle Modification arm ◦ 50% reached goal weight loss ◦ 38% kept the weight off ◦ 74% were exercising at 24 weeks ◦ 58% kept exercising

 Crude Incidence (person-years) ◦ Placebo: 11 ◦ Metformin: 7.8 ◦ ILM: 4.8  Cumulative Incidence (over 3 years) ◦ Placebo: 28.9 % ◦ Metformin: 21.7 % ◦ ILM: 14.4 %

 Incidence of DM was REDUCED by 31% (CI: 17-43) in metformin arm  Incidence of DM was REDUCED by 58% (CI: 48-66) in ILM arm  NNT ◦ Metformin: 13.9 (CI: ) ◦ ILM: 6.9 (CI: )

 Were the patients randomized?  Was randomization concealed?  Were patients similar in prognostic factors? ◦ Table 1  Was the study blinded?  How complete was the follow-up?  Was the study stopped early?  Intention to treat?

 Absolute Risk Reduction ◦ ARR = CER – EER ◦ CER = 28.9% ◦ EER = 14.4%  ARR = 28.9% % = 14.5% In those patients who are high risk for developing DM, when followed for 3 years, 14.3% fewer develop DM if they participate in ILM compared to placebo.

 Relative Risk Reduction ◦ RRR = (CER – EER ) /CER x 100 ◦ CER= 28.9 ◦ EER=14.4 ◦ (28.9% %) / 28.9 % x 100 = 50% Over a 3 year period, there is a 50% decrease in the incidence of DM in ILM group when compared to the placebo group.

 Number Needed to Treat (ILM) ◦ NNT=1/ ARR ◦ 1/0.145 = 7  Number Needed to Treat (metformin) ◦ NNT=1/ARR ◦ 1/0.072 = 14 In order to prevent 1 case of DM over a 3 year period, you would have to treat 7 people with the intensive lifestyle modifications and 14 people with metformin.

 Confidence Intervals and Precision ◦ Number Needed to Treat  ILM: NNT=7 (CI: 5.4 to 9.5)  Metformin: NNT=14 (CI: 8.7 to 33.9) ILM arm is more precise than metformin arm but both are statistically significant.

 UNM, Shiprock and Zuni ◦ DIPS in Zuni  No subgroup analysis of high HbA1Cs vs low HBA1Cs  Subgroup analysis ◦ Metformin arm NOT statistically significant in Hispanics and Native Americans

 Good study BUT it’s a surrogate outcome  Only followed for 3 years… ◦ Blinded arm terminated early  Even with LOW adherence, ILM works! ◦ …but so does metformin!  POLICY CHANGE ◦ Can our patients exercise and do they access to healthy foods?